Table 3.
Immunophenotype assessment in different therapy group
| T cell | No. of trials | No. of patients | MD | 95% CI | p value | |
|---|---|---|---|---|---|---|
| Non-CIK | CIK | |||||
| CD3+ | 6 | 276 | 162 | -0.79 | -1.13 to -0.45 | < 0.001 |
| CD4+ | 5 | 258 | 150 | -2.00 | -2.70 to -1.3 | < 0.001 |
| CD8+ | 5 | 258 | 150 | 3.05 | 2.43 to 3.67 | < 0.001 |
| CD3+ CD8+ | 2 | 57 | 54 | -1.83 | -2.10 to -1.56 | < 0.001 |
| CD4+ CD8+ | 6 | 285 | 188 | 0.04 | 0.03 to 0.05 | < 0.001 |
| CD3+ CD4+ | 2 | 57 | 54 | -2.02 | -2.27 to -1.76 | < 0.001 |
Summary differences of immunophenotype assessment in different therapy group were calculated using the fix-effects model. To assess statistical heterogeneity between studies, the Cochran Q test was performed, with a predefined significance threshold of 0.1.
Note: CIK CIK-containing therapy; CI confidence interval; MD mean difference